$HLVX
HilleVax, Inc.

2024 Q2 Form 10-Q Financial Statement

#000095017024056997 Filed on May 09, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.127M $8.494M
YoY Change 12.39% 46.57%
% of Gross Profit
Research & Development $26.60M $25.98M
YoY Change 15.89% 12.15%
% of Gross Profit
Depreciation & Amortization $400.0K $500.0K
YoY Change 300.0% 49900.0%
% of Gross Profit
Operating Expenses $42.96M $49.80M
YoY Change 42.34% 71.96%
Operating Profit -$42.96M -$49.80M
YoY Change 42.34% 71.96%
Interest Expense $738.0K $727.0K
YoY Change 47.6% 61.92%
% of Operating Profit
Other Income/Expense, Net $2.295M $2.968M
YoY Change 0.57% 43.38%
Pretax Income -$40.67M -$46.83M
YoY Change 45.75% 74.16%
Income Tax
% Of Pretax Income
Net Earnings -$40.67M -$46.83M
YoY Change 45.75% 74.16%
Net Earnings / Revenue
Basic Earnings Per Share -$0.83 -$0.97
Diluted Earnings Per Share -$0.83 -$0.97
COMMON SHARES
Basic Shares Outstanding 49.72M 49.70M
Diluted Shares Outstanding 49.18M 48.46M

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $245.0M $272.7M
YoY Change 0.41% 4.68%
Cash & Equivalents $108.4M $141.1M
Short-Term Investments $136.6M $131.7M
Other Short-Term Assets $7.486M $8.355M
YoY Change -16.72% -10.33%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $252.5M $281.1M
YoY Change -0.2% 4.16%
LONG-TERM ASSETS
Property, Plant & Equipment $10.36M $13.59M
YoY Change -21.15% 30.07%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $23.00K $23.00K
YoY Change 0.0% 4.55%
Total Long-Term Assets $24.41M $33.08M
YoY Change -27.11% 6.35%
TOTAL ASSETS
Total Short-Term Assets $252.5M $281.1M
Total Long-Term Assets $24.41M $33.08M
Total Assets $276.9M $314.2M
YoY Change -3.35% 4.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.850M $2.980M
YoY Change 2449.67% 70.87%
Accrued Expenses $16.00M $19.14M
YoY Change -9.32% 9.94%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $25.67M
YoY Change
Total Short-Term Liabilities $49.17M $25.75M
YoY Change 168.1% 33.6%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $25.45M
YoY Change -100.0% 70.79%
Other Long-Term Liabilities $940.0K $1.700M
YoY Change 1.95% 127.58%
Total Long-Term Liabilities $940.0K $27.15M
YoY Change -96.35% 73.5%
TOTAL LIABILITIES
Total Short-Term Liabilities $49.17M $25.75M
Total Long-Term Liabilities $940.0K $27.15M
Total Liabilities $72.00M $75.27M
YoY Change 6.26% 29.99%
SHAREHOLDERS EQUITY
Retained Earnings -$476.1M -$435.4M
YoY Change 48.87% 49.17%
Common Stock $681.9M $675.2M
YoY Change 26.55% 26.16%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $204.9M $238.9M
YoY Change
Total Liabilities & Shareholders Equity $276.9M $314.2M
YoY Change -3.35% 4.39%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income -$40.67M -$46.83M
YoY Change 45.75% 74.16%
Depreciation, Depletion And Amortization $400.0K $500.0K
YoY Change 300.0% 49900.0%
Cash From Operating Activities -$29.78M -$33.00M
YoY Change 32.84% 106.86%
INVESTING ACTIVITIES
Capital Expenditures $47.00K $153.0K
YoY Change -99.03% -94.87%
Acquisitions
YoY Change
Other Investing Activities -$3.421M -$57.51M
YoY Change -95.98%
Cash From Investing Activities -$3.468M -$57.66M
YoY Change -96.14% 1831.73%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 615.0K 15.06M
YoY Change -93.97% 18727.5%
NET CHANGE
Cash From Operating Activities -29.78M -33.00M
Cash From Investing Activities -3.468M -57.66M
Cash From Financing Activities 615.0K 15.06M
Net Change In Cash -32.63M -75.60M
YoY Change -68.06% 300.88%
FREE CASH FLOW
Cash From Operating Activities -$29.78M -$33.00M
Capital Expenditures $47.00K $153.0K
Free Cash Flow -$29.83M -$33.16M
YoY Change 9.43% 75.06%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001888012
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-41365
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
HILLEVAX, INC.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-0545060
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
321 Harrison Avenue
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02118
CY2024Q1 dei City Area Code
CityAreaCode
617
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
213-5054
CY2024Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
CY2024Q1 dei Trading Symbol
TradingSymbol
HLVX
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2024Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
49720943
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
141076000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
216678000
CY2024Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
131667000
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
86805000
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8355000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7195000
CY2024Q1 us-gaap Assets Current
AssetsCurrent
281098000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
310678000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13592000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14018000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
17831000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
18082000
CY2024Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1631000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1631000
CY2024Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
23000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
25000
CY2024Q1 us-gaap Assets
Assets
314175000
CY2023Q4 us-gaap Assets
Assets
344434000
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2980000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7461000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
19143000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18553000
CY2024Q1 us-gaap Interest And Dividends Payable Current
InterestAndDividendsPayableCurrent
135000
CY2023Q4 us-gaap Interest And Dividends Payable Current
InterestAndDividendsPayableCurrent
134000
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3491000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3118000
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
25749000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
29266000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
22364000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
22831000
CY2024Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
25453000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
25244000
CY2024Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1700000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1568000
CY2024Q1 us-gaap Liabilities
Liabilities
75266000
CY2023Q4 us-gaap Liabilities
Liabilities
78909000
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
49718443
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
48497853
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
49055192
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
47666438
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
5000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2024Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
675242000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
654986000
CY2024Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-950000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-907000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-435388000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-388559000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
238909000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
265525000
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
314175000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
344434000
CY2024Q1 hlvx Research And Development Expense Excluding In Progress Research And Development
ResearchAndDevelopmentExpenseExcludingInProgressResearchAndDevelopment
25978000
CY2023Q1 hlvx Research And Development Expense Excluding In Progress Research And Development
ResearchAndDevelopmentExpenseExcludingInProgressResearchAndDevelopment
23164000
CY2024Q1 hlvx Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
15325000
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8494000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5795000
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
49797000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
28959000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-49797000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-28959000
CY2024Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
2402000
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
2574000
CY2024Q1 us-gaap Interest Expense
InterestExpense
727000
CY2023Q1 us-gaap Interest Expense
InterestExpense
449000
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1293000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-55000
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2968000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2070000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-46829000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-26889000
CY2024Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-121000
CY2024Q1 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Plan Amendments Tax Effect
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansPlanAmendmentsTaxEffect
78000
CY2023Q1 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Plan Amendments Tax Effect
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansPlanAmendmentsTaxEffect
-1000
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-46872000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26890000
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.97
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.97
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.71
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.71
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48460185
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48460185
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37753522
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37753522
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
265525000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5194000
CY2024Q1 us-gaap Stock Granted During Period Value Sharebased Compensation Gross
StockGrantedDuringPeriodValueSharebasedCompensationGross
175000
CY2024Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-121000
CY2024Q1 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
78000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-46829000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
238909000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
267229000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2642000
CY2023Q1 us-gaap Stock Granted During Period Value Sharebased Compensation Gross
StockGrantedDuringPeriodValueSharebasedCompensationGross
80000
CY2023Q1 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
-1000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-26889000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
243061000
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-46829000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-26889000
CY2024Q1 us-gaap Depreciation
Depreciation
456000
CY2023Q1 us-gaap Depreciation
Depreciation
1000
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
5194000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2642000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
251000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
360000
CY2024Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
159000
CY2023Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
126000
CY2024Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
174000
CY2023Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
94000
CY2024Q1 hlvx Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
15325000
CY2024Q1 hlvx Net Accretion Amortization Of Premiums And Discounts On Marketable Securities
NetAccretionAmortizationOfPremiumsAndDiscountsOnMarketableSecurities
-1299000
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1160000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1895000
CY2024Q1 hlvx Increase Decrease In Accounts Payable Accrued Expenses And Other Long Term Liabilities Related Parties
IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLongTermLiabilitiesRelatedParties
-6000
CY2023Q1 hlvx Increase Decrease In Accounts Payable Accrued Expenses And Other Long Term Liabilities Related Parties
IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLongTermLiabilitiesRelatedParties
31000
CY2024Q1 hlvx Increase Decrease In Accounts Payable Accrued Liabilities And Other Long Term Liabilities
IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherLongTermLiabilities
-5180000
CY2023Q1 hlvx Increase Decrease In Accounts Payable Accrued Liabilities And Other Long Term Liabilities
IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherLongTermLiabilities
4384000
CY2024Q1 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
1000
CY2023Q1 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
24000
CY2024Q1 hlvx Increase Decrease In Operating Lease Right Of Use Assets And Liabilities
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities
-94000
CY2023Q1 hlvx Increase Decrease In Operating Lease Right Of Use Assets And Liabilities
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities
1409000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-33002000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15954000
CY2024Q1 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
13825000
CY2024Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
153000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2985000
CY2024Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
92684000
CY2024Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
49000000
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-57662000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2985000
CY2024Q1 hlvx Proceeds From Issuance Of Common Stock Under Share Based Compensation Arrangements
ProceedsFromIssuanceOfCommonStockUnderShareBasedCompensationArrangements
175000
CY2023Q1 hlvx Proceeds From Issuance Of Common Stock Under Share Based Compensation Arrangements
ProceedsFromIssuanceOfCommonStockUnderShareBasedCompensationArrangements
80000
CY2024Q1 hlvx Proceeds From Issuance Of At The Market Offering Net
ProceedsFromIssuanceOfAtTheMarketOfferingNet
14887000
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15062000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
80000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-75602000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-18859000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
218309000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
281032000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
142707000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
262173000
CY2024Q1 us-gaap Interest Paid Net
InterestPaidNet
382000
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
192000
CY2024Q1 hlvx Unpaid In Process Research And Development
UnpaidInProcessResearchAndDevelopment
1500000
CY2024Q1 hlvx Unpaid Property And Equipment Purchases
UnpaidPropertyAndEquipmentPurchases
13000
CY2023Q1 hlvx Unpaid Property And Equipment Purchases
UnpaidPropertyAndEquipmentPurchases
3453000
CY2024Q1 hlvx Accreted Final Interest Payment Fees
AccretedFinalInterestPaymentFees
124000
CY2023Q1 hlvx Accreted Final Interest Payment Fees
AccretedFinalInterestPaymentFees
109000
us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
13529750
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">The preparation of the Company’s unaudited condensed consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company’s condensed consolidated financial statements and accompanying notes. The most significant estimates in the Company’s unaudited condensed consolidated financial statements relate to accruals for research and development expenses. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results could differ materially from those estimates and assumptions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p>
CY2024Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities, and restricted cash. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</span></p>
CY2024Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2024Q1 hlvx Weighted Average Unvested Shares Excluded From Computation Of Earnings Per Share Amount
WeightedAverageUnvestedSharesExcludedFromComputationOfEarningsPerShareAmount
811413
CY2023Q1 hlvx Weighted Average Unvested Shares Excluded From Computation Of Earnings Per Share Amount
WeightedAverageUnvestedSharesExcludedFromComputationOfEarningsPerShareAmount
1492789
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7822350
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5510787
CY2024Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
131794000
CY2024Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2024Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
128000
CY2024Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
131667000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
86811000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
20000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
26000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
86805000
CY2024Q1 hlvx Impairment Of Assets Measured And Carried At Fair Value
ImpairmentOfAssetsMeasuredAndCarriedAtFairValue
0
CY2024Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
14928000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
14898000
CY2024Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1336000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
880000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13592000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14018000
CY2024Q1 us-gaap Depreciation
Depreciation
500000
CY2024Q1 hlvx Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
13818000
CY2023Q4 hlvx Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
12665000
CY2024Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2048000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5233000
CY2024Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1017000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
498000
CY2024Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2260000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
157000
CY2024Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
19143000
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
18553000
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
141076000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
216678000
CY2024Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1631000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1631000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
142707000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
218309000
CY2024Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
799000
CY2023Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
779000
CY2024Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y8M12D
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y
CY2024Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.074
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.074
CY2024Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
896000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2688000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
3688000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
3784000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
3860000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
3974000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
17102000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
35096000
CY2024Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
9241000
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
25855000
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3491000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
22364000
CY2024Q1 us-gaap Description Of Defined Contribution Pension And Other Postretirement Plans
DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans
the Company made matching contributions equal to 100% of the employee’s contributions, subject to a maximum of 4% of eligible compensation. The Company made matching contributions of $0.3 million and $0.2 million during the three months ended March 31, 2024 and 2023, respectively.
CY2022Q4 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
1
CY2022Q4 hlvx Defined Contribution Plan Maximum Eligible Compensation
DefinedContributionPlanMaximumEligibleCompensation
0.04
CY2024Q1 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
300000
CY2023Q1 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
200000
CY2024Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
25000000
CY2024Q1 hlvx Accumulated Paid In Kind Interest Amount
AccumulatedPaidInKindInterestAmount
810000
CY2024Q1 hlvx Debt Instrument Carrying Amount Including Paid In Kind Interest
DebtInstrumentCarryingAmountIncludingPaidInKindInterest
25810000
CY2024Q1 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
357000
CY2024Q1 us-gaap Long Term Debt
LongTermDebt
25453000
CY2024Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
1206000
CY2024Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
8433000
CY2024Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
13303000
CY2024Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
10645000
CY2024Q1 hlvx Principal Payments Interest Payments And Final Payment Fee
PrincipalPaymentsInterestPaymentsAndFinalPaymentFee
33587000
CY2024Q1 hlvx Debt Instrument Interest And Final Payment Fee
DebtInstrumentInterestAndFinalPaymentFee
7777000
CY2024Q1 hlvx Long Term Debt Net Of Interest Pik Interest And Back End Fee
LongTermDebtNetOfInterestPikInterestAndBackEndFee
25810000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.039
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.043
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.019
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.042
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.951
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.962
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.834
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.943
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5194000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2642000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
11.86
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
13.8
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
45100000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1571716
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
8.474
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
1036450
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
15.019
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
13024
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
15.336
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
349439
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
9.426
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
2245703
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
11.319
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
15.02
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
18
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
24200000
CY2024Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
10017725
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-056997-index-headers.html Edgar Link pending
0000950170-24-056997-index.html Edgar Link pending
0000950170-24-056997.txt Edgar Link pending
0000950170-24-056997-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
hlvx-20240331.htm Edgar Link pending
hlvx-20240331.xsd Edgar Link pending
hlvx-ex31_1.htm Edgar Link pending
hlvx-ex31_2.htm Edgar Link pending
hlvx-ex32_1.htm Edgar Link pending
hlvx-ex32_2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
hlvx-20240331_htm.xml Edgar Link completed
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable